New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For WES;ALDW;ABBV;WHF;WGP;ALJ;LRCX;FB;ABT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
January 22, 2015
06:11 EDTFBWhatsApp now available in web browsers
Subscribe for More Information
January 21, 2015
16:00 EDTFBOptions Update; January 21, 2015
iPath S&P 500 VIX Short-Term Futures down 1.63 to 33.49. Option volume leaders: AAPL TSLA TWTR AMZN FB RIG C ABX SIRI NFLX according to Track Data.
14:41 EDTLRCXASML shares higher after reporting Q4 results, raising dividend
Subscribe for More Information
07:44 EDTLRCXLam Research coverage assumed with an Outperform at Credit Suisse
Price target raised to $104 from $85.
January 20, 2015
06:57 EDTFBFacebook to upgrade Messenger app, experiment with revenue generation, WSJ says
Subscribe for More Information
06:02 EDTFBFacebook acquires boutique firm Teehan+Lax, terms not disclosed
Toronto-based boutique firm Teehan+Lax announced in a blog post on Friday that the company will join Facebook's design team in California. T+L said "In a few weeks we will be moving to the San Francisco Bay Area. This will mean saying goodbye to family, friends, Toronto, and Teehan+Lax." Terms of the deal have not been disclosed. Reference Link
January 18, 2015
16:34 EDTFBFacebook job listings hint at push into virtual reality, Reuters says
Subscribe for More Information
January 16, 2015
10:10 EDTABBVAbbVie announces FDA approval of DUOPA enteral suspension
Subscribe for More Information
07:40 EDTALJWolfe Research to hold a conference
1st Annual Oil & Gas 1:1 Refining Conference is being held in Boston on January 16.
07:04 EDTABBVEnanta says EU grants marketing authorizations for AbbVie's Viekirax
Subscribe for More Information
05:05 EDTABBVAbbVie granted marketing authorization by EC for VIEKIRAX + EXVIERA
AbbVie announced that the European Commission has granted marketing authorizations for its all-oral, short-course, interferon-free treatment of VIEKIRAX + EXVIERA. The treatment has been approved with or without ribavirin for patients with genotype 1 chronic hepatitis C virus infection, including those with compensated liver cirrhosis, HIV-1 co-infection, patients on opioid substitution therapy and liver transplant recipients.1,2 Additionally, VIEKIRAX has been approved for use with RBV in genotype 4 chronic hepatitis C patients.
January 15, 2015
11:20 EDTABBVGoldman cuts J&J to sell citing competitive pressures
Subscribe for More Information
January 14, 2015
12:25 EDTABBVAbbVie says pipeline is 'most robust it's ever been'
12:09 EDTABBVAbbVie says 'strongly' committed to dividend, returning cash to shareholders
Subscribe for More Information
12:00 EDTABBVAbbVie says guidance to be further refined as HCV launch progresses
11:59 EDTABBVAbbVie repeats FY15 adjusted EPS view $4.25-$4.45, consensus $4.30
Subscribe for More Information
10:27 EDTFBFacebook, Google seen at front of 'multi-year' positive run for Internet stocks
Subscribe for More Information
09:46 EDTFBFacebook initiated with a Buy at Rosenblatt
Target $100.
07:17 EDTFBFacebook price target raised to $100 from $88 at Oppenheimer
Subscribe for More Information
07:13 EDTFBFacebook price target raised to $102 on FAN contribution at Credit Suisse
Credit Suisse raised Outperform rated Facebook's price target to $102 from $88 to reflect new mobile ad network FAN into its estimates. The analyst expects Premium Video to have a greater impact on 2015 financials and longer-term for new products and yet-to-be monetized properties to continue to drive estimates.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use